A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY)

Nicholas Geremia,Gianfranco Sanson,Luigi Principe,Roberta Maria Antonello,Verena Zerbato,Roberto Luzzati,ITANAEROBY study group,Stefano Di Bella,Alberto Enrico Maraolo,Daniele Roberto Giacobbe,Chiara Sepulcri,Simone Ambretti,Richard Aschbacher,Laura Bartolini,Mariano Bernardo,Alessandra Bielli,Marina Busetti,Davide Carcione,Giulio Camarlinghi,Edoardo Carretto,Tiziana Cassetti,Chiara Chilleri,Francesco Giuseppe De Rosa,Saveria Dodaro,Raffaele Gargiulo,Francesca Greco,Anna Knezevich,Jari Intra,Tommaso Lupia,Erika Concialdi,Gabriele Bianco,Francesco Luzzaro,Carola Mauri,Gianluca Morroni,Adriana Mosca,Elisabetta Pagani,Eva Maria Parisio,Claudio Ucciferri,Chiara Vismara
DOI: https://doi.org/10.1016/j.anaerobe.2024.102901
IF: 2.837
2024-08-28
Anaerobe
Abstract:C: perfringens bloodstream infections (BSIs) can be associated with high mortality rates. We performed a subanalysis of all C. perfringens BSIs enrolled during a multicentric retrospective observational study (ITANAEROBY). Data were collected from January 2016 to December 2020. C. perfringens BSIs were 134 (134/1960, 6.8%). The highest resistance rate was observed for clindamycin (26/120, 21.6%), penicillin (11/71, 15.4%) and metronidazole (14/131, 10.7%). In conclusion, C. perfringens reduced susceptible phenotype to first-line therapy.
What problem does this paper attempt to address?